Atlas Trials

Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis

Clinical trial NCT05071716 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT05071716
Sponsor
Bausch Health Americas, Inc.
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Hepatic Encephalopathy
Start date
2022-04-07
Primary completion
2025-09-01
Enrollment
524

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.